Ironwood Pharmaceuticals

Ironwood Pharmaceuticals

Biotechnology Research

Boston, MA 29,919 followers

Ironwood is on a mission to advance treatment of gastrointestinal diseases & redefine the standard of care for patients

About us

At Ironwood Pharmaceuticals, we are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients. As a pioneer and champion in the development of a market-leading therapy for IBS-C and CIC, we are singularly focused on advancing the treatment of GI diseases and continue to challenge what has been done before to shape what the future holds. So, we named ourselves after the Ironwood tree, which can live for thousands of years in the harshest desert, creating a shaded microclimate in which life thrives. Iron, like science, is undeniable and strong. Wood, like artistry and humanity, is flexible, resilient and versatile. The two words together represent our passion for making a positive impact on the health – and lives- of GI patients, their families and communities. Our core values: •Transform Patient Lives: Leverage our insights, capabilities, and expertise to see the most critical patient needs. •Innovate Meaningfully: Think boldly, experiment proactively, and take initiative to create new possibilities in the GI world. •Challenge and Collaborate: Encourage different opinions and points of views in decision-making. •Practice Humanity: Recognize that our people are the cornerstone of Ironwood. •Own The Outcome: Honor our commitments to our patients, stakeholders, and one another by upholding a performance-driven culture.

Website
https://ironwoodpharma.com/
Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Boston, MA
Type
Public Company
Founded
1998

Locations

Employees at Ironwood Pharmaceuticals

Updates

Similar pages

Browse jobs

Stock

IRWD

NASDAQ

20 minutes delay

$6.32

Open
6.32
Low
6.26
High
6.41

Data from Refinitiv

See more info on Bing

Funding

Ironwood Pharmaceuticals 10 total rounds

Last Round

Post IPO debt

US$ 150.0M

See more info on crunchbase